Coherus Biosciences Inc (NASDAQ:CHRS) has received an average broker rating score of 1.00 (Strong Buy) from the three brokers that provide coverage for the stock, Zacks Investment Research reports. Three equities research analysts have rated the stock with a strong buy rating.
Analysts have set a one year consensus price target of $42.67 for the company and are anticipating that the company will post ($1.74) EPS for the current quarter, according to Zacks. Zacks has also given Coherus Biosciences an industry rank of 73 out of 265 based on the ratings given to its competitors.
Shares of Coherus Biosciences (NASDAQ:CHRS) opened at 22.96 on Monday. Coherus Biosciences has a 12 month low of $15.50 and a 12 month high of $38.10. The stock has a 50 day moving average price of $26.19 and a 200 day moving average price of $28.04. The firm’s market cap is $892.96 million.
Coherus Biosciences (NASDAQ:CHRS) last announced its earnings results on Monday, November 9th. The company reported ($1.86) EPS for the quarter. The firm earned $7.20 million during the quarter, compared to analyst estimates of $16.10 million. On average, equities research analysts expect that Coherus Biosciences will post ($5.76) EPS for the current year.
In related news, insider Alan C. Herman sold 11,333 shares of the company’s stock in a transaction on Tuesday, December 1st. The shares were sold at an average price of $29.49, for a total value of $334,210.17. Following the completion of the sale, the insider now owns 211,865 shares in the company, valued at approximately $6,247,898.85. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Christos Richards sold 15,000 shares of the company’s stock in a transaction on Friday, November 13th. The shares were sold at an average price of $27.49, for a total transaction of $412,350.00. Following the completion of the sale, the director now owns 63,836 shares of the company’s stock, valued at approximately $1,754,851.64. The disclosure for this sale can be found here.
An institutional investor recently raised its position in Coherus Biosciences stock. Jennison Associates boosted its position in Coherus Biosciences Inc (NASDAQ:CHRS) by 0.7% during the third quarter, according to its most recent Form 13F filing with the SEC. The hedge fund owned 355,998 shares of the company’s stock after buying an additional 2,635 shares during the period. Jennison Associates owned approximately 0.30% of Coherus Biosciences worth $7,134,000 as of its most recent filing with the SEC.
Several brokerages have recently commented on CHRS. Barclays began coverage on Coherus Biosciences in a report on Monday, November 23rd. They issued an “overweight” rating and a $46.00 target price on the stock. Zacks Investment Research downgraded Coherus Biosciences from a “hold” rating to a “sell” rating in a report on Friday, October 9th.
Coherus BioSciences, Inc. is a late-stage clinical biologics platform company focused on the global biosimilar market. The Company’s clinical-stage pipeline consists of two anti-inflammatory agents targeting tumor necrosis factor (NASDAQ:CHRS), and a long-acting form of granulocyte colony-stimulating factor (G-CSF). The Company’s product pipeline includes anti-TNF product candidate, CHS-0214, an etanercept (Enbrel) biosimilar candidate which is in Phase III clinical trials, and anti-TNF product candidate, CHS-1420, an adalimumab (Humira) biosimilar candidate which is in Phase III clinical trials. The Company also offers G-CSF product candidate, CHS-1701, a pegfilgrastim (Neulasta) biosimilar which has completed a Phase I study.
For more information about research offerings from Zacks Investment Research, visit Zacks.com